Key result
TERT promoter -124C>T mutation linked to ~78% lower mortality risk in ovarian clear cell carcinoma.
Why the study?
Patients with advanced or recurrent ovarian clear cell carcinoma are chemotherapy-resistant with poor prognosis, prompting the need to identify specific prognostic markers.
Does the -124C>T mutation in the TERT promoter indicate a favorable prognosis in patients with ovarian clear cell carcinoma?
Cohort (n=169)
No
Does the -124C>T mutation in the TERT promoter indicate a favorable prognosis in patients with ovarian clear cell carcinoma?
Hazard Ratio: 0.216 (95% CI 0.05–0.934)
p-value: p=0.040
The -124C>T mutation in the TERT promoter is an independent favorable prognostic factor for overall survival in patients with ovarian clear cell carcinoma.
The -124C>T TERT promoter mutation was associated with favorable survival in OCCC; leaves open its role in risk stratification pending prospective validation.
Purpose Ovarian clear cell carcinoma (OCCC) is the second most common type of epithelial ovarian cancer. Patients with advanced or recurrent OCCC were resistant to chemotherapy and had poor prognosis. The purpose of this study was to identify specific prognostic markers in ovarian clear cell carcinoma. Methods A cohort of 169 patients with OCCC were enrolled, and their clinicopathological features were reviewed. Mutations in the TERT promoter and PIK3CA gene were detected by Sanger sequencing in 87 and 109 cases, respectively. Immunohistochemical markers for ARID1A, HDAC6, Cyclin E1, and p53 were stained on the tissue microarrays. Kaplan-Meier curves and Cox regression analysis were used to assess the correlation between these parameters and prognosis. Results The overall survival (OS) and progression-free survival (PFS) of patients with the − 124 C > T mutation in the TERT promoter were significantly longer than those of wild-type patients. The − 124 C > T mutation was an independent factor associated with a favorable OS. Patients with the − 124 C > T mutation were more likely to have a normal preoperative serum CA125 level (P = 0.017), a higher prevalence of single nucleotide polymorphism (SNP) (P = 0.014), and a lower probability of relapse (P = 0.025) than wild-type patients. No correlation between other factors and prognosis was observed in this cohort. Conclusion Our results suggest that the − 124C > T mutation in the TERT promoter may serve as a favorable prognostic factor for overall survival in patients with OCCC.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2024) conducted a cohort in Ovarian clear cell carcinoma (n=169). -124C>T mutation in the TERT promoter vs. Wild-type TERT promoter was evaluated on Overall survival (HR 0.216, 95% CI 0.050-0.934, p=0.040). The -124C>T mutation in the TERT promoter was an independent favorable prognostic factor for overall survival in patients with ovarian clear cell carcinoma (HR 0.216).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: